Thus, we undertook a prospective analysis of plasma OPG levels and breast cancer risk in 206 women with a BRCA1 or BRCA2 mutation that were unaffected by breast cancer at the time of study enrollment. This evidence concerns the gene TNFRSF11B and breast carcinoma.